These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37279819)

  • 1. Nitric oxide synthase inhibitors as potential therapeutic agents for gliomas: A systematic review.
    Merenzon MA; Hincapie Arias E; Bhatia S; Shah AH; Higgins DMO; Villaverde M; Belgorosky D; Eijan AM
    Nitric Oxide; 2023 Sep; 138-139():10-16. PubMed ID: 37279819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of nitric oxide synthase in matrix metalloproteinase-9- and/or urokinase plasminogen activator receptor-mediated glioma cell migration.
    Zhuang T; Chelluboina B; Ponnala S; Velpula KK; Rehman AA; Chetty C; Zakharian E; Rao JS; Veeravalli KK
    BMC Cancer; 2013 Dec; 13():590. PubMed ID: 24325546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
    Ohtsu N; Takaoka K; Segawa E; Hashitani S; Noguchi K; Kishimoto H; Urade M
    Oncol Rep; 2010 Jul; 24(1):31-6. PubMed ID: 20514441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting iNOS As a Valuable Strategy for the Therapy of Glioma.
    Maccallini C; Gallorini M; Cataldi A; Amoroso R
    ChemMedChem; 2020 Feb; 15(4):339-344. PubMed ID: 31851765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
    Maccallini C; Di Matteo M; Gallorini M; Montagnani M; Graziani V; Ammazzalorso A; Amoia P; De Filippis B; Di Silvestre S; Fantacuzzi M; Giampietro L; Potenza MA; Re N; Pandolfi A; Cataldi A; Amoroso R
    Eur J Med Chem; 2018 May; 152():53-64. PubMed ID: 29689474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-bis(2-chloroethyl)-1-nitrosourea in c6 glioma cells.
    Yin JH; Yang DI; Chou H; Thompson EM; Xu J; Hsu CY
    J Pharmacol Exp Ther; 2001 Apr; 297(1):308-15. PubMed ID: 11259558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipopolysaccharide plus 12-o-tetradecanoylphorbol 13-acetate induction of migration and invasion of glioma cells in vitro and in vivo: Differential inhibitory effects of flavonoids.
    Shen SC; Lin CW; Lee HM; Chien LL; Chen YC
    Neuroscience; 2006 Jun; 140(2):477-89. PubMed ID: 16580779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Selective Acetamidine-Based iNOS Inhibitor CM544 Reduces Glioma Cell Proliferation by Enhancing PARP-1 Cleavage In Vitro.
    Gallorini M; Maccallini C; Ammazzalorso A; Amoia P; De Filippis B; Fantacuzzi M; Giampietro L; Cataldi A; Amoroso R
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOS Expression and NO Function in Glioma and Implications for Patient Therapies.
    Tran AN; Boyd NH; Walker K; Hjelmeland AB
    Antioxid Redox Signal; 2017 Jun; 26(17):986-999. PubMed ID: 27411305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effects of nitric oxide synthase inhibitor L-NAME on oral squamous cell carcinoma: a preliminary study.
    Shang ZJ; Li ZB; Li JR
    Int J Oral Maxillofac Surg; 2006 Jun; 35(6):539-43. PubMed ID: 16497478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is There a Role for Temozolomide in Glioma Related Seizures? A Systematic Review.
    Yue J; Yin C; Chen L; Xu R; Zhao D
    Neurol India; 2022; 70(3):864-871. PubMed ID: 35864610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
    Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
    Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The implications of nitric oxide metabolism in the treatment of glial tumors.
    Mazurek M; Rola R
    Neurochem Int; 2021 Nov; 150():105172. PubMed ID: 34461111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide Chronotherapy in Glioma: A Systematic Review.
    Jia JL; Alshamsan B; Ng TL
    Curr Oncol; 2023 Feb; 30(2):1893-1902. PubMed ID: 36826108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathodynamics of nitric oxide production within implanted glioma studied with an in vivo microdialysis technique and immunohistochemistry.
    Oyoshi T; Nomoto M; Hirano H; Kuratsu J
    J Pharmacol Sci; 2003 Jan; 91(1):15-22. PubMed ID: 12686726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide.
    Nakano S; Matsukado K; Black KL
    Cancer Res; 1996 Sep; 56(17):4027-31. PubMed ID: 8752174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.